|
gptkbp:instanceOf
|
gptkb:company
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Lemonaid_Health
|
|
gptkbp:acquisitionYear
|
2021
|
|
gptkbp:address
|
gptkb:349_Oyster_Point_Blvd,_South_San_Francisco,_CA_94080,_USA
|
|
gptkbp:CEO
|
gptkb:Anne_Wojcicki
|
|
gptkbp:dataPrivacyConcern
|
genetic data sharing
|
|
gptkbp:FDAApproved
|
direct-to-consumer genetic health risk tests
|
|
gptkbp:foundedBy
|
gptkb:Anne_Wojcicki
gptkb:Linda_Avey
gptkb:Paul_Cusenza
|
|
gptkbp:foundedYear
|
2006
|
|
gptkbp:headquartersLocation
|
gptkb:Sunnyvale,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
23andMe Holding Co.
|
|
gptkbp:industry
|
gptkb:biotechnology
personal genomics
|
|
gptkbp:languageOfService
|
English
|
|
gptkbp:legalForm
|
Delaware corporation
|
|
gptkbp:notableEvent
|
went public via SPAC merger in 2021
|
|
gptkbp:notableInvestment
|
gptkb:Google
gptkb:Sequoia_Capital
gptkb:New_Enterprise_Associates
|
|
gptkbp:notableProduct
|
gptkb:23andMe+_Membership
gptkb:23andMe_Personal_Genome_Service
|
|
gptkbp:notableWinner
|
gptkb:Time_50_Best_Inventions_2008
|
|
gptkbp:numberOfEmployees
|
~700
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:partner
|
GlaxoSmithKline
|
|
gptkbp:partnershipPurpose
|
drug discovery
|
|
gptkbp:product
|
genetic testing kits
ancestry reports
health risk reports
|
|
gptkbp:regulates
|
gptkb:FDA
|
|
gptkbp:servesArea
|
gptkb:Canada
gptkb:Europe
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:serviceType
|
ancestry analysis
direct-to-consumer genetic testing
health risk analysis
pharmacogenetics
|
|
gptkbp:SPACMergerWith
|
gptkb:VG_Acquisition_Corp.
|
|
gptkbp:stockSymbol
|
gptkb:NASDAQ
ME
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.23andme.com/
|
|
gptkbp:bfsParent
|
gptkb:23andMe
|
|
gptkbp:bfsLayer
|
6
|